675 related articles for article (PubMed ID: 27580700)
41. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal AC; Castro-Santamaria R; Freedland SJ
Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
[TBL] [Abstract][Full Text] [Related]
42. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
43. [Clinical outcomes after combined therapy with dutasteride in patients with unsuccessful trial without catheter after treatment with an alpha1-adrenergic receptor blocker monotherapy for acute urinary retention caused by prostatic hyperplasia].
Inahara M; Sugiura M; Kaga K; Hou K; Araki K; Masuda H; Kojima S; Naya Y
Nihon Hinyokika Gakkai Zasshi; 2014 Oct; 105(4):190-5. PubMed ID: 25757349
[TBL] [Abstract][Full Text] [Related]
44. Re: Rates of Prostate Surgery and Acute Urinary Retention for Benign Prostatic Hyperplasia in Men Treated with Dutasteride or Finasteride.
Kaplan SA
J Urol; 2017 Oct; 198(4):719-721. PubMed ID: 28905745
[No Abstract] [Full Text] [Related]
45. Comparisons of the Efficacy and Safety of Finasteride and Dutasteride for Benign Prostatic Hyperplasia: A Network Meta-Analysis.
Yin T; Qiao Z; Li Y; Li D; Jiang M; An C; Wang F; Zuo M; Hu K; Li Q
Am J Ther; 2017; 24(5):e517-e523. PubMed ID: 26322675
[TBL] [Abstract][Full Text] [Related]
46. Cost effectiveness comparison of dutasteride and finasteride in patients with benign prostatic hyperplasia--The Markov model based on data from Montenegro.
Dabanović V; Kostić M; Janković S
Vojnosanit Pregl; 2016 Jan; 73(1):26-33. PubMed ID: 26964381
[TBL] [Abstract][Full Text] [Related]
47. Finasteride or dutasteride for the pharmacological treatment for male lower urinary tract symptoms due to benign prostatic hyperplasia?
Alcántara-Montero A; Brenes-Bermúdez FJ
Actas Urol Esp; 2016 May; 40(4):268-9. PubMed ID: 26774534
[No Abstract] [Full Text] [Related]
48. Treatment of benign prostatic hyperplasia and occurrence of prostatic surgery and acute urinary retention: a population-based cohort study in the Netherlands.
Souverein PC; van Riemsdijk MM; de la Rosette JJ; Opdam PC; Leufkens HG
Eur Urol; 2005 Apr; 47(4):505-10. PubMed ID: 15774250
[TBL] [Abstract][Full Text] [Related]
49. The clinical applications of five-alpha reductase inhibitors.
Loughlin KR
Can J Urol; 2021 Apr; 28(2):10584-10588. PubMed ID: 33872554
[TBL] [Abstract][Full Text] [Related]
50. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes.
Roehrborn CG; McConnell JD; Saltzman B; Bergner D; Gray T; Narayan P; Cook TJ; Johnson-Levonas AO; Quezada WA; Waldstreicher J;
Eur Urol; 2002 Jul; 42(1):1-6. PubMed ID: 12121721
[TBL] [Abstract][Full Text] [Related]
51. [Combination drug therapy in patients with BPH].
Kuzmenko AV; Kuzmenko VV; Gyaurgiev TA
Urologiia; 2018 Mar; (1):101-105. PubMed ID: 29634142
[TBL] [Abstract][Full Text] [Related]
52. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
Marberger MJ
Urology; 1998 May; 51(5):677-86. PubMed ID: 9610579
[TBL] [Abstract][Full Text] [Related]
53. Is There a Role for Preoperative 5 Alpha Reductase Inhibitors in Reducing Prostate Vascularity and Blood Loss?
Bruha M; Welliver C
Curr Urol Rep; 2017 Oct; 18(10):75. PubMed ID: 28766115
[TBL] [Abstract][Full Text] [Related]
54. Model-based meta-analysis of the time to first acute urinary retention or benign prostatic hyperplasia-related surgery in patients with moderate or severe symptoms.
D'Agate S; Chavan C; Manyak M; Palacios-Moreno JM; Oelke M; Michel MC; Roehrborn CG; Della Pasqua O
Br J Clin Pharmacol; 2021 Jul; 87(7):2777-2789. PubMed ID: 33247951
[TBL] [Abstract][Full Text] [Related]
55. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.
Toren P; Margel D; Kulkarni G; Finelli A; Zlotta A; Fleshner N
BMJ; 2013 Apr; 346():f2109. PubMed ID: 23587564
[TBL] [Abstract][Full Text] [Related]
56. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
57. Understanding Treatment Response in Individual Profiles of Men with Prostatic Enlargement at Risk of Progression.
Gravas S; Palacios-Moreno JM; Thompson D; Concas F; Kamola PJ; Roehrborn CG; Oelke M; Kattan MW; Averbeck MA; Manyak M; Cortés V; Lulic Z
Eur Urol Focus; 2023 Jan; 9(1):178-187. PubMed ID: 35985933
[TBL] [Abstract][Full Text] [Related]
58. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.
Chou CH; Lin CL; Lin MC; Sung FC; Kao CH
J Endocrinol Invest; 2015 Jul; 38(7):799-805. PubMed ID: 25778849
[TBL] [Abstract][Full Text] [Related]
59. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
60. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
O'Leary MP; Roehrborn C; Andriole G; Nickel C; Boyle P; Höfner K
BJU Int; 2003 Aug; 92(3):262-6. PubMed ID: 12887480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]